Breaking News, Collaborations & Alliances

Lilly, Sanford-Burnham Enter Immunological R&D Alliance

Will combine biotech capabilities to develop therapies for autoimmune disorders

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eli Lilly and Co. and Sanford-Burnham Medical Research Institute will collaborate to discover and develop immunological therapies using biotechnology approaches targeting multiple immune checkpoint modulators for the treatment of diseases such as lupus, Sjögren’s Syndrome, inflammatory bowel disease and other autoimmune disorders.   Lilly will contribute its biotechnology capabilities and expertise in immunology, and Sanford-Burnham will apply its expertise in cellular pathways regulating ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters